Augmenix

SpaceOAR Hydrogel is a medical device designed to minimize the side effects of radiation therapy for prostate cancer patients by creating a protective space between the rectum and the prostate. This innovative hydrogel spacer reduces the likelihood of high-dose radiation reaching the rectum, thereby improving the quality of life for patients undergoing prostate cancer treatment. The company primarily serves healthcare providers and prostate cancer patients, operating within the medical device market. SpaceOAR Hydrogel is FDA cleared and has been validated through extensive clinical research, with over 220,000 patients treated worldwide. The business model revolves around the sale of the hydrogel product to medical institutions and practitioners, generating revenue through product sales and potentially through partnerships with healthcare providers.

Keywords: Hydrogel, Prostate Cancer, Radiation Therapy, Rectal Spacer, Medical Device, FDA Cleared, Clinical Research, Patient Quality, Healthcare Providers, Treatment Outcomes.